

International Pharmaceuticals

\$279 million

in revenue in 2016

Our International Pharmaceuticals businesses included: Paladin Labs, headquartered in Montreal, Canada; SOMAR, headquartered in Mexico City, Mexico; and Litha, headquartered in Midrand, South Africa.

Segment Milestones

- Paladin Labs secured Canadian rights to XIAFLEX® and launched the product in the fourth-quarter 2016
- Paladin Labs launched NUCYNTA® in the fourth-quarter 2016
- Initiated a sales process for Litha and related Sub-Saharan African business assets. The sale was announced in February 2017 and expected to close in the second-quarter 2017



By the Numbers

4,900

Endo has approximately 4,900 employees worldwide

\$4.01

Endo total 2016 revenue was \$4.01 Billion

250

U.S. Generic Pharmaceuticals has a portfolio of over 250 product families

200

U.S. Generic Pharmaceuticals has over 200 products in our pipeline including approximately 120 ANDAs currently under review with the FDA

20

U.S. Generics launched approximately 20 new products in 2016 including first-to-file quetiapine ER and ezetimibe tablets

+18%

U.S. Specialty Branded Pharmaceuticals performance +18% in 2016

\$190

XIAFLEX® achieved US sales of \$190 million, a 20% increase vs. prior year

30

Endo pursuing an indication for cellulite after XIAFLEX® demonstrated a highly statistically significant Ph2b data in cellulite; approximately 30 million women identified with self-reported cellulite